Extend the life of liver cancer patients! Bristol-Myers Squibb Company's (BMY.US) first-line immunotherapy combination therapy approved by the European Union.
Bristol-Myers Squibb (BMY.US) announced that the European Commission (EC) has approved its blockbuster PD-1 inhibitor Opdivo (nivolumab) in combination with CTLA-4 targeted antibody Yervoy (ipilimumab) for the first-line treatment of unresectable or advanced hepatocellular carcinoma (HCC) in adult patients.
Bristol-Myers Squibb Company (BMY.US) announced that the European Commission (EC) has approved its blockbuster PD-1 inhibitor Opdivo (nivolumab) in combination with the CTLA-4 targeted antibody Yervoy (ipilimumab) for the first-line treatment of unresectable or advanced hepatocellular carcinoma (HCC) in adults. According to reports, the US FDA has accepted a supplemental biologics license application for Opdivo in combination with Yervoy for the same patient population, with a review expected to be completed by April 21 of this year.
Public information shows that Opdivo is a PD-1 immune checkpoint inhibitor designed to help restore anti-tumor immune responses by utilizing the body's own immune system to fight cancer. Yervoy, on the other hand, targets and inhibits CTLA-4. CTLA-4 antibodies enhance T cell activity to increase tumor-killing capabilities.
Data shows that the combination treatment of Opdivo and Yervoy significantly prolongs patients' overall survival (OS), meeting the primary clinical endpoint of the trial. The median OS for patients in the Opdivo plus Yervoy combination therapy group was 23.7 months (95% CI: 18.829.4), compared to 20.6 months (95% CI: 17.522.5) for patients in the active control drug group, with a hazard ratio of 0.79 (0.650.96; p=0.018). The OS benefit was consistent across various patient subgroups.
Related Articles

Nanhua Futures' overseas subsidiary (603093.SH) obtained clearing membership qualification from the Chicago Mercantile Exchange.

Subsidiary of Jiangsu Guoxin Corp., Ltd. (002608.SZ) - Guoxin Shazhou has put a 1 million kilowatt unit into operation

Fiberhome Telecommunication Technologies (600498.SH) has received approval from the China Securities Regulatory Commission for its A-share private placement application.
Nanhua Futures' overseas subsidiary (603093.SH) obtained clearing membership qualification from the Chicago Mercantile Exchange.

Subsidiary of Jiangsu Guoxin Corp., Ltd. (002608.SZ) - Guoxin Shazhou has put a 1 million kilowatt unit into operation

Fiberhome Telecommunication Technologies (600498.SH) has received approval from the China Securities Regulatory Commission for its A-share private placement application.

RECOMMEND

Hong Kong Financial Secretary: Targeting Issuance of Stablecoin Licenses Within This Year
07/07/2025

Putin Advocates for Expanded Use of Local Currency Settlements and Proposes New BRICS Investment Platform
07/07/2025

Ministry of Housing and Urban-Rural Development Issues Latest Statement, Emphasizing Stronger Measures to Stabilize the Real Estate Market
07/07/2025